King, Anthony JHudson, JemmaAzuara-Blanco, AugustoBurr, JenniferKernohant, AshleighHomer, TaraShabaninejad, HoseinSparrow, John MGarway-Heath, DavidBarton, KeithNorrie, JohnDavidson, TraceyVale, LukeMacLennan, GraemeTAGS Study Group2024-07-162024-07-162024-07-01King, A J, Hudson, J, Azuara-Blanco, A, Burr, J, Kernohant, A, Homer, T, Shabaninejad, H, Sparrow, J M, Garway-Heath, D, Barton, K, Norrie, J, Davidson, T, Vale, L, MacLennan, G & TAGS Study Group 2024, 'Evaluating Primary Treatment for People with Advanced Glaucoma : Five-Year Results of the Treatment of Advanced Glaucoma Study', Ophthalmology, vol. 131, no. 7, pp. 759-770. https://doi.org/10.1016/j.ophtha.2024.01.0070161-6420ORCID: /0000-0002-1039-5646/work/153542678https://hdl.handle.net/2164/23818Funding Information: The author(s) have made the following disclosure(s): The TAGS was supported by a Grant from the National Institute of Health and Care Research - Health Technology Assessment Program - 12/35/38. J.H.: Financial support – National Institute for Health Research Health Technology Assessment Programme. A.K.: Financial support – National Institute for Health Research Health Technology Assessment Programme T.H.: Financial support – National Institute for Health Research Health Technology Assessment Programme H.S.: Financial support – National Institute for Health Research Health Technology Assessment Programme J.M.S.: Financial support – National Institute for Health Research Health Technology Assessment Programme D.G.-H.: Consultant – AbbVie, Omikron, Santen, Roche; Financial support – National Institute for Health Research Health Technology Assessment Programme and Efficacy and Mechanism Evaluation (EME) Programme, MRC DPFS, Horizon 2020, Janssen R&D LLC, Santen; Royalties – Heidelberg Engineering; Lecturer – Viatris, Omikron, Novartis, AbbVie; Patent – UCL, Cardiff/UCL, City University of London; Leadership or fiduciary role – European Glaucoma Society, Glaucoma Research Society, Investigative Ophthalmology and Visual Science K.B.: Consultant – iStar, EyeDPharma, Laboratoires Thea, Advanced Ophthamic Innovations, ELT Sight, Sight Sciences, Shifamed/Myra Medical, Tarsier Pharma, Radiance TX; Financial support – Advanced Ophthamic Innovations, AISG, Ahtens Glaucoma Congress, Moroccan Glaucoma Society, ARPS - Singapore; Lecturer – Alcon, Allergan, Laboratoires Thea, Santen Pharmaceutical Co. Ltd.; Patent – National University of Singapore; Leadership or fiduciary role – ELT Sight; Equity owner – Vision Futures Limited, Vision Medical Events Ltd., Aquesys, MedEther Ophthalmology, International Glaucoma Surgery Registry J.N.: Financial support – National Institute for Health Research L.V.: Financial support – National Institute for Health Research Health Technology Assessment Programme G.M.: Financial support – National Institute for Health Research Health Technology Assessment Programme and EME Programme Obtained funding: N/A121072524engIntraocular pressureOpen-angle glaucomaQuality of lifeRandomized controlled trialVisual field lossRE OphthalmologyOphthalmologySupplementary Datahttps://ars.els-cdn.com/content/image/1-s2.0-S0161642024000162-mmc1.pdfhttps://ars.els-cdn.com/content/image/1-s2.0-S0161642024000162-mmc2.pdfhttps://ars.els-cdn.com/content/image/1-s2.0-S0161642024000162-mmc3.pdfhttps://ars.els-cdn.com/content/image/1-s2.0-S0161642024000162-mmc4.pdfREJournal article10.1016/j.ophtha.2024.01.007http://www.scopus.com/inward/record.url?scp=85186194701&partnerID=8YFLogxK1317